F Consonni1, M G Abate, D Galli, G Citerio. 1. Neurorianimazione, Dipartimento di Medicina Perioperatoria e Terapie Intensive, Ospedale San Gerardo, Via Pergolesi 33, 20052 Monza, MI, Italy. xconson@aliceposta.it
Abstract
OBJECT: In order to monitor cerebral autoregulation status, a software package was developed to calculate a cerebral autoregulation index (pressure reactivity index, PRx). The aim of this study is to evaluate whether the application of this methodology is feasible and useful in the clinical setting. DESIGN: Prospective observational study. SETTING: NeuroIntensive Care Unit (NICU) of a university-affiliated teaching hospital. PATIENTS AND PARTICIPANTS: Twenty-six consecutive patients admitted to NICU requiring intracranial pressure (ICP) and invasive arterial pressure (AP) monitoring. MEASUREMENTS AND RESULTS: Patient's data were collected for a total of 902 h. Mean PRx was calculated utilizing 2 h time window. CPP-PRx distribution graphs were calculated from CPP of 20 to 110 mmHg using 10 mmHg intervals. Autoregulation was preserved in 18% observations (83/451) and deranged in 49% observations (220/451). In 33% observations (148/451), autoregulation could not be clearly defined (0 < PRx < 0.2). Even if no clinical protocol was developed, autoregulation status information inserted in clinical decision pathway influenced clinical management. Mean CPP, calculated at maximum and minimum ICP every 2 h interval, resulted different between groups with good and poor reactivity (67 +/- 17.6 and 85 +/- 20.0 mmHg, respectively, for autoregulating observations and 60 +/- 19.1 and 67 +/- 19.4 mmHg, respectively, for nonautoregulating observations, P < 0.001, independent samples t-test). PRx values were normally distributed. CONCLUSIONS: Our study demonstrates that a daily bedside measure of cerebral autoregulation is feasible. PRx values can support clinicians in the identification of a targeted CPP in patients suffering from different intracranial pathologies and requiring an intensive monitoring.
OBJECT: In order to monitor cerebral autoregulation status, a software package was developed to calculate a cerebral autoregulation index (pressure reactivity index, PRx). The aim of this study is to evaluate whether the application of this methodology is feasible and useful in the clinical setting. DESIGN: Prospective observational study. SETTING: NeuroIntensive Care Unit (NICU) of a university-affiliated teaching hospital. PATIENTS AND PARTICIPANTS: Twenty-six consecutive patients admitted to NICU requiring intracranial pressure (ICP) and invasive arterial pressure (AP) monitoring. MEASUREMENTS AND RESULTS:Patient's data were collected for a total of 902 h. Mean PRx was calculated utilizing 2 h time window. CPP-PRx distribution graphs were calculated from CPP of 20 to 110 mmHg using 10 mmHg intervals. Autoregulation was preserved in 18% observations (83/451) and deranged in 49% observations (220/451). In 33% observations (148/451), autoregulation could not be clearly defined (0 < PRx < 0.2). Even if no clinical protocol was developed, autoregulation status information inserted in clinical decision pathway influenced clinical management. Mean CPP, calculated at maximum and minimum ICP every 2 h interval, resulted different between groups with good and poor reactivity (67 +/- 17.6 and 85 +/- 20.0 mmHg, respectively, for autoregulating observations and 60 +/- 19.1 and 67 +/- 19.4 mmHg, respectively, for nonautoregulating observations, P < 0.001, independent samples t-test). PRx values were normally distributed. CONCLUSIONS: Our study demonstrates that a daily bedside measure of cerebral autoregulation is feasible. PRx values can support clinicians in the identification of a targeted CPP in patients suffering from different intracranial pathologies and requiring an intensive monitoring.
Authors: Susan L Bratton; Randall M Chestnut; Jamshid Ghajar; Flora F McConnell Hammond; Odette A Harris; Roger Hartl; Geoffrey T Manley; Andrew Nemecek; David W Newell; Guy Rosenthal; Joost Schouten; Lori Shutter; Shelly D Timmons; Jamie S Ullman; Walter Videtta; Jack E Wilberger; David W Wright Journal: J Neurotrauma Date: 2007 Impact factor: 5.269
Authors: Luzius A Steiner; Jonathan P Coles; Andrew J Johnston; Marek Czosnyka; Tim D Fryer; Peter Smielewski; Doris A Chatfield; Raymond Salvador; Franklin I Aigbirhio; John C Clark; David K Menon; John D Pickard Journal: J Cereb Blood Flow Metab Date: 2003-11 Impact factor: 6.200
Authors: Luzius A Steiner; Marek Czosnyka; Stefan K Piechnik; Piotr Smielewski; Doris Chatfield; David K Menon; John D Pickard Journal: Crit Care Med Date: 2002-04 Impact factor: 7.598
Authors: L A Steiner; J P Coles; M Czosnyka; P S Minhas; T D Fryer; F I Aigbirhio; J C Clark; P Smielewski; D A Chatfield; T Donovan; J D Pickard; D K Menon Journal: J Neurol Neurosurg Psychiatry Date: 2003-06 Impact factor: 10.154
Authors: L A Steiner; M Balestreri; A J Johnston; J P Coles; D A Chatfield; J D Pickard; D K Menon; M Czosnyka Journal: Acta Neurochir Suppl Date: 2005
Authors: Kenneth Brady; Brijen Joshi; Christian Zweifel; Peter Smielewski; Marek Czosnyka; R Blaine Easley; Charles W Hogue Journal: Stroke Date: 2010-07-22 Impact factor: 7.914